Independent research coverage of ASX-listed Life Science companies
Ferry at the end of a rainbow on Sydney Harbour, August 2014
|
In its relatively short history the Life Sciences industry has created hundreds of billions of dollars in shareholder value, through names like Amgen, Biogen Idec, Celgene, Gilead, Medtronic, Regeneron and Shire.
Companies such as these are successful because they encourage daring innovation, out of which comes breakthrough drugs and medical devices that significantly change lives for the better. In the 21st Century Life Sciences has become a truly global industry, flourishing wherever economic freedom and an entrepreneurial culture combines with first-class education and healthcare systems. That's why we believe Australia and New Zealand have the potential to create multiple billion-dollar companies from its rapidly emerging Life Sciences sector. NDF Research was founded in 2016 to provide equity research coverage of this exciting opportunity, focused on Life Sciences companies that are publicly traded on the Australian Securities Exchange (ASX). NDF Research believes that ASX-listed companies have been largely overlooked in the global Life Sciences boom that began in late 2008, partly because of a paucity of quality research on them. NDF Research's goal is to help fill this great need, and introduce investors to some potential future billion dollar companies from 'Down Under'. |
About usMeet Stuart Roberts, founder of NDF Research and our Senior Analyst
|
What we doLearn how we provide valuable and much-needed independent research coverage of the Life Sciences sector in Australia
|
About our sectorLearn why Australia and New Zealand are the undiscovered gem of the global Life Sciences sector
|
Copyright © 2016 NDF Research